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ABSTRACT
Background and aims Smoking in pregnancy causes substantial avoidable harm to mothers and offspring; nicotine re-
placement therapy (NRT) may prevent this, and is used to help women to quit. A recently updated Cochrane Review of
randomized controlled trials (RCTs) investigating impacts of NRT in pregnancy focuses primarily on efficacy data, but also
reports adverse impacts fromNRT. Herewe identify and summarize NRT impacts on adverse pregnancy outcomes reported
in non‐randomized controlled trials (non‐RCTs).Methods Systematic reviews and meta‐analyses of RCTs and non‐RCT
studies of NRT in pregnancy, with design‐specific risk of bias assessment and grading of recommendations, assessment,
development and evaluations (GRADE) criteria applied to selected outcomes. Findings Relevant Cochrane Review
findings are reported alongside those from this new review. Seven RCTs were included; n= 2340. Ninemeta‐analyses were
performed; non‐statistically significant estimates indicated potentially reduced risk from NRT compared with smoking for
mean birth weight, low birth weight, preterm birth, intensive care admissions, neonatal death, congenital anomalies
and caesarean section and potentially increased risks for miscarriage and stillbirth. GRADE assessment for mean birth
weight and miscarriage outcomes indicated ‘low’ confidence in findings. Twenty‐three non‐RCTs were included;
n = 931163. Eleven large studies from five routine health‐care cohorts reported clinical outcomes; 12 small studies
investigated mainly physiological outcomes within in‐patient women given NRT. Findings from meta‐analyses for
congenital anomalies, stillbirth andpretermbirthwereunderpowered andnot in a consistent direction; GRADE assessment
of confidence in findings was ‘very low’. Routine health‐care studies were of higher quality, but implications of reported
findings were unclear as there was inadequate measurement and reporting of women’s smoking. Conclusions Available
evidence from randomized controlled trials and non‐randomized comparative studies does not currently provide clear
evidence as to whether maternal use of nicotine replacement therapy during pregnancy is harmful to the fetus.
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INTRODUCTION
Smoking in pregnancy has adverse effects on the health of
pregnantwomen and their offspring in the pre‐ and perina-
tal periods and in later life [1–3]. Smoking rates are highest
among younger, socially disadvantaged pregnant women
[4,5], and up to 38% of socio‐economic inequalities in still-
births and infant deaths can be attributed to smoking [6].
Stopping smoking in pregnancy improves birth outcomes
[7] and reduces the burden of health‐care costs to the
National Health Service (NHS) [8].
The National Institute for Health and Care Excellence
(NICE) recommends nicotine replacement therapy (NRT)
in those women who are unable to stop smoking with
non‐pharmacological interventions [9]. However, even
when pregnant women choose NRT, many do not use this
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for very long [10] and adherence to NRT by pregnant
women tends to be lower than in non‐pregnant smokers
[10–12]. This poor adherencemay at least partially explain
why NRT has been found to be less effective when used in
pregnancy [13]. One possible reason for poor adherence
to NRT in pregnancy is maternal concern about the safety
of NRT. Qualitative interviews with pregnant women who
sought support from NHS Stop Smoking Services demon-
strated that they often reported using NRT intermittently
or stopping courses early due to safety concerns [14].
There is a strong theoretical rationale for using NRT to
avoid smoking in pregnancy; even if women do not stop
smoking completely, cigarette smoke exposes the fetus to
numerous toxins whereas NRT exposes them to only nico-
tine, and so is very likely to be safer [15]. A Cochrane Re-
view investigating the impacts of NRT in pregnancy has
recently been updated [13]. RCTs produce the least biased
evidence but they also generally have small sample sizes,
such that even when they are combined in meta‐analyses,
small adverse impacts may not be detected. Well‐
conducted, large non‐RCTstudiesmay be still prone to bias,
but comprehensive confounder‐adjustment could aug-
ment RCT data and provide sufficient power to investigate
infrequent health outcomes following NRT use in preg-
nancy. The Cochrane Review focuses primarily on efficacy
data, with adverse effects reported as secondary outcomes.
Consequently, we conducted a systematic review of
non‐RCT studies reporting usually adverse fetal or infant
health outcomes after pregnant women’s use of NRT. Here
we report this process alongside the safety‐orientated find-
ings from the updated Cochrane Review [13], with the aim
of providing a comprehensive, objective and contemporary
assessment of whether and how use of NRT during gesta-
tion affects pregnancy outcomes.
METHODS
Randomized controlled studies (RCTs)
Standard Cochrane Review (CR) methods used are de-
scribed in the published review [13]. Searches, for RCTs
only, were concluded by 20 May 2019 and from included
studies we extracted data on the following outcomes:
miscarriage/spontaneous abortion; stillbirth; birth weight;
low birth weight (< 2500 g); preterm birth (< 37 weeks’
gestation); neonatal intensive care unit admissions; neona-
tal death; caesarean section; congenital anomalies; infant
development; and respiratory symptoms. We assessed
study quality using Cochrane’s ‘risk of bias’ tool. A priori,
we planned to use grading of recommendations, assess-
ment, development and evaluations (GRADE) criteria for
birth weight and miscarriage/spontaneous abortion out-
comes, to report studies separately where in
meta‐analyses I2 > 75%, and to conduct subgroup analy-
ses for placebo and non‐placebo RCTs.
Non‐RCTs
A study protocol, written in accordance with the Preferred
Reporting Items for Systematic Reviews andMeta‐analyses
(PRISMA) statement, was registered on PROSPERO
(International Prospective Register of Systematic Reviews)
[16,17].
Inclusion criteria
We sought published non‐RCT studies, of any design, in
any language, reporting empirical data on potentially ad-
verse fetal or infant health outcomes following NRT expo-
sure or nicotine administration in pregnancy. Although
we wanted to identify all health outcomes, we anticipated
a priori that thesewould include at least some of the impor-
tant clinical outcomes in a relevant 2015 Cochrane
Review [18] (see below).
Exclusion criteria
We excluded RCTs and studies which reported only
smoking‐cessation outcomes [18].
Search strategy
A search strategy was developed in MEDLINE and then
adapted for the CINAHL, Embase, PsycINFO, CAB Ab-
stracts, Social Sciences Citation Index and Economic and
Social Research Council databases. Supporting informa-
tion, Table S1 gives search terms; we combined those rele-
vant to pregnancy and fetal health with those referring to
NRT or nicotine use. NRT became available in the 1980s,
so we searched between 1980 and 12 June 2020,
hand‐searching references from retrieved full texts, includ-
ing references from texts excluded from the review.
Authors were contacted, as required, for study details.
Study selection and data extraction
One reviewer screened titles and abstracts, rejecting those
which were not eligible for inclusion and retrieving manu-
scripts which appeared potentially includable or about
which there was uncertainty. Two reviewers indepen-
dently screened the full texts and a consensus decision
was made on inclusion: if consensus was not possible, a
third reviewer adjudicated. Study data were extracted by
one reviewer and checked by a second, using a piloted form
within Covidence (web‐based systematic review platform)
[19]. Extracted data included: author’s details, publication
date, study design and objectives, recruitment and data col-
lection methods, participants’ characteristics and study
outcomes. For NRT exposure, we extracted data
concerning when women were issued with or reported
using this, and howmany times and by whatmethod these
data were acquired. We also extracted smoking behaviour
data, and particularly any information on smoking before
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and after NRT use, including how often and by what
means, this was recorded.
Quality assessment
Two researchers independently quality‐assessed studies
using modified versions of the Newcastle–Ottawa scale
(NOS) [20]. Disagreements about scoring were discussed
and consensus reached using a third assessor, if necessary.
One modified scale was created for studies in which NRT
was used as part of routine clinical care; this had a maxi-
mum score of eight stars. The other was used for smaller
cohorts in which NRT was an experimental intervention
(maximum score: seven stars). Both assessed three do-
mains: ‘selection’, ‘design and analysis’ and ‘outcome’,
and were modified by removal of the ‘demonstration that
outcome of interest was not present at start of study’ item
as pregnancy outcomes could only occur at childbirth.
The ‘comparability’ domain was renamed ‘design and
analysis’, and we removed ‘was follow up long enough for
outcomes to occur?’ from the ‘outcome’ domain.
Supporting information, Appendix S1 details scale modifi-
cations and scoring.
Meta‐analysis and GRADE criteria
We anticipated substantial variation in study designs and
outcomes, so decisions about meta‐analyses were made
only after consideration of all included studies. Where ap-
propriate, we planned to pool data comparing outcomes
following NRT exposure with no NRT exposure. To provide
contextual information within the same studies we also
compared outcomes following reported NRTexposure with
those after smoking.
We created three exposure groups; those women who:
(i) were prescribed or reported being given or using NRT,
(ii) reported smoking but not being given NRT or (iii) nei-
ther reported smoking nor using NRT. As the only indica-
tion for using NRT in pregnancy is as a substitute for
smoking, we assumed that all women issued with NRT
would have smoked prior to this, so where studies catego-
rized women as only having used NRT and not having
smoked, we combined these groups with NRT‐exposed
groups from other studies which did not make this claim.
Hence, we assumed that all women issued NRTwould have
smoked at some point in pregnancy. Review Manager ver-
sion 5 software generated pooled risk ratios (RR) using a
random‐effects model and an estimate of heterogeneity
using the I2 statistic from the Mantel–Haenszel model
[21]. As non‐RCTs and RCTs are subject to very different
biases and effects from unmeasured confounding, we de-
cided to present non‐RCT and RCT studies in separate
meta‐analyses. We anticipated that confounding due to
women’s smoking before, during or after use of NRT was
likely to be particularly important to estimates derived from
meta‐analyses of non‐RCTs, as few empirical studies
attempted to adjust for this.
Table 1 shows GRADE [22] criteria that were applied to
assess strength of evidence for each meta‐analysed out-
come. These rate the quality or certainty of evidence as
‘very low’, ‘low’, ‘moderate’ or ‘high quality’; ratings start
at ‘high quality’ for RCTs and ‘low quality’ for observa-
tional studies and GRADE criteria are used to
up/downgrade ratings, as appropriate. Two reviewers inde-
pendently applied criteria for eachmeta‐analysed outcome;
disagreements were resolved by consensus [13].
RESULTS
RCTs
Full results, including the PRISMA diagram, are found in
the published CR [13], but of nine RCTs which investigated
NRT use in pregnancy, seven reported infant and fetal
safety outcomes [23–29] and all were conducted in high‐
income countries (n = 2340). All RCTs recruited pregnant
women who smoked and, as with non‐RCTs, pregnancies
would have been exposed to tobacco smoke before women
joined trials. RCT groups all received either behavioural
support alone or with a placebo, or active NRT. Four
placebo‐RCTs were judged to be at low [23,24,26,29]
and two non‐placebo RCTs at high risk of bias [25,28];
for the remaining study this was unclear [27]. High bias
risk was generally allocated to studies with no placebo
control.
All seven studies reported mean birthweight and gesta-
tional age at delivery and incidences of low birth weight
(below 2500 g). Six reported rates of preterm birth (birth
before 37 weeks), miscarriage or spontaneous abortion
and stillbirth [23,24,26–29] and four reported rates of in-
fants’ admissions to special care and of neonatal death
[23,24,26,28]. Three trials reported rates of congenital
malformation [23,24,27] and two reported caesarean sec-
tion rates [23,24]. One study [30] reported infants’ ‘sur-
vival without developmental impairment’ and respiratory
symptoms at 2 years.
Meta‐analysis results: RCTs
Figure 1 shows RCT meta‐analyses findings. There was no
evidence of a difference in risk of miscarriage/spontaneous
abortion between NRT and control groups [RR = 1.60,
95% confidence interval (CI) = 0.53–4.83, I2 = 0%;
Fig. 1.1]. Similarly, there was no evidence of a difference
between the numbers of stillbirths in the NRT and control
groups (RR = 1.24, 95% CI = 0.54 to 2.84, I2 = 0%;
Fig. 1.2). The pooled estimate for birth weight was higher
for the NRT than for the control group, but the CIs incorpo-
rated a small decrease in birth weight as well as a more
substantial increase, and heterogeneity was high [mean
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difference (MD) = 99.73 g, 95% CI = –6.65 to 206.10,
I2 = 70%; Fig. 1.3]. There was no evidence of a difference
in the incidence of low birth weight and there was much
heterogeneity in the analysis (RR = 0.69, 95%
CI = 0.39–1.20, I2 = 69%; Fig. 1.4).
Analyses of rates of preterm births (RR = 0.81, 95%
CI = 0.59–1.11, I2 = 21%; Fig. 1.5), neonatal intensive
care unit admissions (RR = 0.90, 95% CI = 0.64–1.27;
I2 = 0%; Fig. 1.6) and neonatal deaths (RR = 0.66, 95%
CI = 0.17 to 2.62, I2 = 0%; Fig. 1.7) all resulted in CIs
spanning one, incorporating the potential for both benefit
and harm. Similarly, meta‐analyses of congenital
anomalies and caesarean birth suggested no clear evidence
for a benefit or harm from NRT (congenital anomalies:
RR = 0.73, 95% CI = 0.36–1.48, I2 = 0%, Fig. 1.8; caesar-
ean section: RR = 1.18, 95% CI = 0.83–1.69, I2 = 46%,
Fig. 1.9).
GRADE assessment found a ‘low’ certainty of evidence
for mean birth weight and miscarriage/spontaneous abor-
tion outcomes.
Narratively reported outcomes: RCTs
Two RCTs [23,24] reported the distribution of Apgar scores
at 5 minutes after birth, cord arterial blood pH, intraven-
tricular haemorrhage, neonatal convulsions, necrotizing
enterocolitis, mechanical ventilation of infant, assisted vag-
inal delivery andmaternal death between NRTand placebo
groups; no statistically significant differences were noted.
One RCT [30] reported infant outcomes after the neonatal
period. Using a composite self‐report outcome based on the
Ages and Stages Questionnaire, 3rd edition instrument
[31], significantly better infant developmental outcomes
were observed in infants born to women who had been
randomized to NRT compared to those in the placebo
group. The odds ratio (OR) for infants reaching 2 years of
age ‘without developmental impairment’ (i.e. normal de-
velopment) was 1.40 (95% CI = 1.05–1.86). However,
there was no difference in parental reports of infants’ respi-
ratory symptoms; the OR for reporting of any respiratory
problem in the NRT group was 1.32 (95% CI = 0.97–
1.74).
Non‐RCT studies
Study selection, characteristics and outcome measures
A total of 18467 titles and abstracts were identified and, af-
ter duplicate removal, 9391 records were screened.
Forty‐five full text articles were retrieved and 23 were in-
cluded in the review; Fig. 2 shows the reasons for study
exclusion.
Table 2 presents characteristics of the 23 included
studies (n = 931 163). Eleven were conducted in
health‐care settings, used routine clinical data [32–42],
compared women prescribed or issued NRT with those
who were not and were derived from five discrete
birth cohorts. A UK cohort reported outcomes in two
manuscripts [32,34] and a PhD [38]; a Danish cohort
reported outcomes in five papers [33,35,37,39,42] and
Canadian [40], US [36] and Australian [41] cohorts
were reported in single studies. Eleven studies described
Table 1 GRADE criteria for assessing non‐RCTs.
GRADE
criteria Reasons to downgrade
Risk of bias Studies scoring< 6/8 for risk of bias in the quality assessment were reviewed and if perceived to have such a high risk of
bias that they could threaten findings’ accuracy, downgrading by one level occurred
Inconsistency If I2 was> 50%, effect estimates for each study in the meta‐analysis were assessed. If they were very different, with little‐
to‐no overlap of the confidence intervals around studies’ effect estimates, rating was downgraded by one level
Indirectness This criterion assesses if evidence included in the review directly answers the review question. Quality of evidence was not
downgraded based on this criterion due to the problem/patient/population, intervention/indicator, comparison, outcome
(PICO) criteria used when searching.We felt our narrow PICO criteria meant that all studies included were reporting data
that answered the review question, as we wanted information on all health outcomes reported after NRT exposure in
pregnancy
Imprecision If the confidence interval for the effect estimate was so wide that it could be consistent with having an effect in either
direction, this was deemed to be a sign of imprecision and rating was downgraded by one level
Publication
bias
Quality of evidence not downgraded based on this criterion due to the types of studies appraised
Upgrading Quality of evidence not upgraded as there was no supporting evidence for the three recommended reasons to upgrade:
large magnitude of effect, the presence of a dose–response gradient or that the effect of all plausible confounding factors
would be to reduce the effect seen. It is also not recommended to upgrade a downgraded outcome
Criteria derived from the grading of recommendations, assessment, development and evaluation (GRADE) Working Group Handbook [22]. For all criteria,
meta‐analysed studies’ quality was judged against reasons to downgrade. If there was serious concern regarding any criteria (except ‘upgrading’), quality
of evidence was downgraded to ‘very low’ quality, from the starting level of ‘low’ for observational (non‐randomized controlled trial) studies.
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NRT administration to small, experimental interventional
cohorts of inpatient pregnant women who usually
smoked but were temporarily abstinent [43–53], and were
based in Sweden [43,48], the United States [45,46,49–
53], the United Kingdom [44] and Finland [47]. These
mainly compared short‐term fetal and maternal physio-
logical observations when abstinent and using NRT to
those when women smoked. The final Danish study was
interventional; participants were a subgroup of women
in a quasi‐RCT who had been offered and accepted
NRT [54].
Maternal age was reported by 17 studies [32–36,38–
40,43,45,46,48–53] and used as a confounder in analy-
ses, but not reported in three [33,37,41,42].
Socio‐economic status or education level was reported by
11 studies [32–40,42,51]. Maternal comorbidities were in-
cluded as confounders in six routine health‐care studies
[32,34,37,38,40,41], and as exclusion criteria in five
interventional studies [46,50–53]. One interventional
study reported comorbidities for each participant and
analysed data by condition [44].
NRT exposure data was obtained from electronic medi-
cal records or prospectively from telephone interviews in
nine routine health‐care studies [32–35,37–39,41,42];
two others collected data retrospectively via
self‐administered postal questionnaires [36,40] sent 3–
8 years [40] and 2–3 months [36] after pregnancy. Al-
though women in the Danish cohort were asked in which
gestational weeks they had used NRT or smoked, manu-
scripts did not report the details [33,35,37,39,42] and
one routine health‐care study reported median duration
of NRT use but not when, in pregnancy, this occurred
[40]. All 12 interventional studies reported women’s gesta-
tional ages at NRT administration, with nine providing
mean gestational ages at exposure (range = 21.5–
35.6 weeks) [45,46,48–54].
Figure 1 Meta‐analyses of randomized controlled trials (RCTs) (from Cochrane Review). [Colour figure can be viewed at wileyonlinelibrary.com]
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Table 2 shows which studies reported or adjusted for
women’s smoking before or after NRTuse. Of the six studies
in meta‐analyses, three reported women’s smoking behav-
iour before NRT use/exposure [33,36,39], but data were
collected by questionnaire at set time‐points, so no
smoking behaviour information was available later in par-
ticipants’ pregnancies. Consequently, many pregnant
women in NRT‐exposed arms of meta‐analyses will also
have smoked, and exposures to NRT and smoking are not
completely differentiated. Two routine health‐care studies
adjusted for smoking status during NRT use [33,37]. Two
routine health‐care studies recruited only pregnant
women who smoked, and investigated impacts of using
NRTwithin this group [40,41]. Experimental studies all re-
corded women’s smoking status at the time of recruitment,
and nine also validated abstinence just before NRT was
given to women [43–46,48–52] and two followed partici-
pants until childbirth, collecting some information on
smoking after NRT exposure [53,54].
Table 3 summarizes studies’ outcomes. Routine
health‐care cohorts reported pregnancy outcomes such
as congenital anomalies [34,35], birth weight [36–40],
gestational age at birth [36,37,39,40] and stillbirth
[32,33]. Interventional studies generally monitored physi-
ological observations, including biophysical pro-
files [49,52], umbilical and uterine artery Dopplers
Figure 2 Preferred Reporting Items for Systematic Reviews andMeta‐analyses (PRISMA) flow diagram: non‐RCT review. PRISMA [17] flow diagram
showing study selection and reasons for study exclusion. *Hand searches of references located, a PhD thesis and an unpublished study at the time of
searching known to the authors.
Figure 1 Continued.
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[45,46,50], fetal breathing [43,44] and heart rate [43,46–
48,50,51] and maternal blood pressure and heart rate
[43,46–52]; some also reported pregnancy outcomes
[48,52–54].
Quality assessment
Table 4 reports quality assessments. Routine health‐care
studies had amedian score of 6/8 stars [interquartile range
(IQR) = 5–7] and low scores often reflected a lack of valida-
tion of participants’ exposures (e.g. NRT use), retrospective
exposure assessment or a lack of adverse outcome valida-
tion. Interventional studies’ median score was 4/7 stars
(IQR = 2.5–4.5); these often scored poorly on cohort repre-
sentativeness but relatively well for having biochemical
validation of smoking abstinence.
Meta‐analysis outcomes
We performed meta‐analyses for congenital anomalies,
stillbirth and preterm birth outcomes, but for others this
was not possible due to differences in study designs. Analy-
ses only included routine health‐care studies. As
interventional cohorts used ‘before–after’ designs without
appropriate comparison groups, the few which reported
birth outcomes could not be included. The study which in-
vestigated a subsample of quasi‐RCT intervention group
participants selected intervention and comparison groups
in very different ways, and was judged unsuitable for inclu-
sion [54].
Major congenital anomalies after first‐trimester NRT
exposure were reported using the European Surveillance
of Congenital Anomalies and Twins (EUROCAT) classifica-
tion system in two studies [34,35,56]. Stillbirth rate was
reported in two; one study defined this as a baby born not
showing signs of life at ≥ 28 weeks [32] and the other after
20 weeks [33]; we pooled these, as both represented death
in later pregnancy. One interventional study reported fetal
deaths but was excluded for the reason outlined above
[54]. Preterm birth (at < 37 weeks) was an outcome in
six studies, but only two were pooled [36,37]; three were
without appropriate comparison groups [40,41,54]
and one [39] duplicated findings from another included
study [37].










Bérard 2016 [40] ★★★ ★ ★ ★★★★★
Dhalwani 2018 [32] ★★★★ ★ ★ ★★★★★★
Dhalwani 2015 [34] ★★★★ ★ ★ ★★★★★★
Dhalwani 2014 [38] ★★★★ ★ ★ ★★★★★★
Gaither 2009 [36] ★★ ★ ★ ★★★★
Lassen 2010 [37] ★★★★ ★ ★★ ★★★★★★★
Milidou 2012 [39] ★★★★ ★ ★★★★★
Morales‐Suárez‐Varela 2006 [35] ★★★★ ★ ★★ ★★★★★★★
Strandberg‐Larsen 2008 [33] ★★★★ ★ ★★ ★★★★★★★
Torp‐Pedersen 2010 [42] ★★★★ ★ ★★ ★★★★★★★










Bruner 1991 [45] ★ ★ ★★ ★★★★
Gennser 1975 [43] ★ ★ ★★ ★★★★
Hegaard 2004 [54] ★ ★
Lehtovirta 1983 [47] ★ ★
Lindblad 1987 [48] ★★ ★ ★ ★★★★
Manning 1976 [44] ★ ★ ★★
Ogburn Jr 1999 [49] ★★ ★ ★★ ★★★★★
Oncken 1997 [46] ★★ ★ ★★ ★★★★★
Oncken 1996 [50] ★★ ★★ ★★★★
Oncken 2009 [51] ★★ ★ ★★ ★★★★★
Schroeder 2002 [53] ★ ★★ ★★★
Wright 1997 [52] ★ ★★ ★★★
Quality assessment scores for routine health‐care and interventional cohort studies as assessed by the modified Newcastle–Ottawa scale [20]; see Supporting
information, Appendix S1 for scales. RCTs = randomized controlled trials.
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Meta‐analysis results: non‐RCTs
Figure 3 shows non‐RCTmeta‐analysis findings. Compared
with no NRT use, there was no evidence for an association
between using NRT and risks of congenital anomalies
(RR = 1.17, 95% CI = 0.97–1.42, I2 = 0%; Fig. 3.1) or
stillbirth (RR = 1.14, 95% CI = 0.63–2.04, I2 = 56%;
Fig. 3.2). Similarly, when compared to smoking, NRT use
was not associated with anomalies (RR = 1.06, 95%
CI = 0.86–1.32, I2 = 0%) or stillbirth (RR = 0.75, 95%
CI = 0.41–1.36, I2 = 54%). Compared with no NRT use,
meta‐analysis of two studies suggested a slightly increased
risk of preterm birth (RR = 1.25, 95% CI = 1.07–1.46,
I2 = 0%; Fig. 3.3) but, compared to smoking, NRT was
not associated with greater preterm birth risk
(RR = 1.12, 95% CI = 0.95–1.33, I2 = 0%). For ‘NRT ver-
sus no NRT’ comparisons GRADE criteria certainty of evi-
dence for these outcomes was ‘very low’.
Narratively reported outcomes: non‐RCTs
Table 3 reports outcomes by study. Two studies excluded
from the pretermbirthmeta‐analysis compared risks of pre-
term birth followingNRTuse inwomenwho smoked; there
was a significantly reduced risk in NRT users compared to
non‐users in one paper (adjusted OR = 0.21, 95%
CI = 0.13–0.34) [40], while the second showed no signifi-
cant difference (HR = 1.00, 95% CI = 0.71–1.42) [41].
Four studies reported mean gestational age at birth for
NRT‐exposed women [40,48,52,53] but only one, which
enrolled only women who smoked, had a comparison
group [40]; with no statistical comparison, this reported
a mean (standard deviation (SD)) birth gestational age in
NRT users of 38.9 (1.9) weeks and in non‐NRT users of
37.5 (3.3).
Three studies reported small for gestational age (SGA)
rates [40,41,54]. Two included only women who smoked,
with one reporting a significantly reduced risk of SGA in
those using NRT compared to those who did not (adjusted
OR = 0.61, 95% CI = 0.41–0.90) [40] and the other
showing no significant change in risk (HR = 0.77, 95%
CI = 0.56–1.07) [41]. The other study used very different
methods for selecting exposure groups rendering these
non‐comparable, but reported no significant difference in
SGA rates [54].
Mean birth weight was reported by six studies
[37,38,40,48,52,53], three were interventional
[48,52,53] and three had comparison groups which were
too dissimilar to be aggregated [37,38,40]. One of these en-
rolled women who smoked reported, with no statistical
comparison, a mean birth weight (SD) in NRT users of
3257.9 g (553.1) and non‐users of 2943.5 g (733.5)
[40]. A PhD thesis using medical record data compared
mean birth weight in NRT users and women who neither
smoked nor used NRT in pregnancy and found these were
lower (β = 168 g, 99% CI = –214 to 122, P < 0.001)
Figure 3 Meta‐analyses of non‐randomized controlled trials (RCTs). [Colour figure can be viewed at wileyonlinelibrary.com]
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[38]. Within a multivariate analysis which adjusted for re-
ported smoking behaviour, a population‐based cohort
found no statistically significant associations between du-
ration of NRT use and mean birth weight (β = 0.25 g per
week of NRT use, CI = –2.31 to 2.81) [37].
Low birth weight (less than 2500 g) was reported by
three studies which seemed similar enough to be aggre-
gated, but due to heterogeneity (I2 = 76%) are presented
separately [36,38,39]. One reported low birth weight inci-
dences of 2.4% in unexposed women, 2.9% in NRT users,
4.8% of women who smoked and used NRT and 4.3% in
smokers [39]. A retrospective questionnaire study found
that 13.1% of NRT‐exposed women delivered low birth
weight infants and rates were 9.26% within women who
smoked and 6.99% with neither exposure [36]. Another
study reported that NRT exposure was associated with
increased risk of low birth weight when compared to no
exposure (OR = 1.88, 99% CI = 1.42–2.49, P < 0.001)
[38]. Two of these studies had the lowest quality scores of
all routine health‐care studies (see Table 4) [36,39].
Fetal death, a composite of stillbirth and miscarriage
[38], delivery mode [38], infantile colic [39] and infant
strabismus [42], were reported in single studies and Table 2
reports these findings. Compared with no NRT use, expo-
sure was associated with reduced risk of fetal death
(OR = 0.44, 99% CI = 0.38–0.50, P < 0.001) [38]
and of assisted delivery (relative RR (RRR) = 0.68,
99% CI = 0.54–0.85, P < 0.001) but not with in-
creased risk of caesarean section [38]. A study of women
who smoked who were exposed to NRT reported a com-
posite outcome: ‘any adverse perinatal event’,
encompassing a number of separate birth outcomes
[41]. Table 2 reports the individual outcome HRs, but
there was no significant change in overall risk of any ad-
verse perinatal event when comparing women who
smoked who were exposed to NRT and those who were
not (HR = 1.02, 95% CI = 0.84–1.23).
Table 5 presents physiological outcomes measured by
study. In nine studies, fetal physiological observations were
recorded at baseline and compared to readings taken when
abstinent and using NRT [43–46,48–52]. Three also com-
pared these within‐patient changes from baseline with
those recorded during or after smoking following a similar
period of abstinence [43,45,46]. Results showed no consis-
tent patterns, and most studies did not report significant
outcome changes after NRT administration.
DISCUSSION
Key findings
Overall, we found no evidence that NRT used by pregnant
women who smoke has adverse impacts on fetal and infant
outcomes. Although underpowered, the direction of
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suggest that NRT is not likely to have adverse impacts or be
more harmful than smoking in pregnancy. The robustness
of non‐RCT evidence was poor, with meta‐analyses’ find-
ings affected by imprecision or potential biases, which
may explain the inconsistency in the direction of associa-
tions found in non‐RCT meta‐analyses. NRT‐exposed
women are likely to have smoked at some point in preg-
nancy but, generally, this was not measured and so could
not be adjusted for in non‐RCTs, making interpretation of
these studies’ findings particularly difficult.
Strengths and limitations
Our synthesis meta‐analyses of non‐RCTstudies are limited
by the inherent biases in these study designs. An issue was
that ascertainment of NRT exposure relied upon maternal
self‐report or prescription records. Women’s recall may
not have been perfect and, as some women prescribed
NRT will not have used it, using prescription records could
overestimate NRTexposure. More importantly, studies gen-
erally assessed NRT exposure at only one or two
time‐points in pregnancy and in most, smoking intensity
either before or after NRT use was not reported, despite
smoking being known to adversely affect outcomes. The
omission of detailed smoking data from non‐RCT reports
was probably the greatest threat to these studies’ validity.
It is logical to assume that all women issued NRT would
have smoked at least in early pregnancy, and this will have
tended to reduce differences between exposure groups’ out-
comes. Only two non‐RCT studies adjusted for smoking be-
haviour [33,37]; others could be subject to confounding of
unknown magnitude. Another important issue was that
NRT prescribing involved confounding by indication [57].
In three of the five birth cohorts which provided non‐RCT
studies’ data, women issued with NRT had higher rates of
comorbidities and lower socio‐economic status than other
women who smoked, and so very probably experienced
‘higher‐risk’ pregnancies [10,33,36] which may have sub-
stantially affected adverse outcomes. We believe that our
modified NOS for non‐RCTs’ quality assessments and the
application of GRADE criteria should help readers to under-
stand the degree to which observed associations might be
causal or due to bias, confounding or chance.
For the non‐RCT review, only one reviewer screened ti-
tles and abstracts and extracted data; although another
person checked this, there was no parallel independent
screening or extraction by the second researcher, so re-
searcher bias is a possibility. Additionally, some non‐RCTs
may not have been indexed in databases, but we are confi-
dent that our comprehensive search strategy will have
found all which were and, hopefully, methods for assessing
bias and certainty of non‐RCT evidence assist the findings’
interpretation.
Strengths of this work include applying ‘Cochrane‐type’
review methods to find all available and relevant RCTs and
non‐RCTs. We believe this is the first attempt to systemati-
cally retrieve and synthesize all studies which report fetal
and infant health outcomes after pregnant women have
used or been offered NRT, and that we have successfully
identified, assessed and presented together all relevant
studies. This, coupled with objective methods for assessing
studies’ biases and the strength of evidence produced by
meta‐analyses, should provide a thorough report of what
is known about the impact of NRTon pregnancyoutcomes.
Similar reviews have had less thorough search strategies,
presented only narrative data or have not attempted to as-
sess bias [15,58,59]. While meta‐analyses are underpow-
ered, these remain the strongest currently available data
on NRTsafety in pregnancy, and strengths and weaknesses
of the literature are highlighted. The juxtaposition of
non‐RCT and RCT meta‐analyses is perhaps the most use-
ful feature of the review, and is illustrated by considering
findings regarding preterm birth. For this outcome,
meta‐analysis of two non‐RCT studies revealed a statisti-
cally significant association between NRT use and higher
rates of prematurity in which we have ‘very low’ certainty.
However, meta‐analysis of data from seven RCTs provides a
non‐statistically significant ‘best estimate’ for this associa-
tion being in the opposite (protective) direction. This direct
comparison helps the reader tomore clearly appreciate and
consider the quality of available data before drawing con-
clusions. This disparity might be explained by women’s
smoking either before, after or alongside NRT exposure,
which was generally not adjusted for by non‐RCTs.
Smoking is well known to contribute to increased risk of
pre‐term birth [60], and one of the included studies in this
meta‐analysis acknowledges that the women recom-
mended or prescribed NRT by a health‐care professional
might be those who smoke more heavily [36] and find it
harder to quit [61].
Findings in context of previous literature
The most robust research on the safety of NRT in preg-
nancy comes from RCTs, and we report meta‐analyses for
nine safety‐orientated outcomes [13]. In RCTs there is no
confounding by indication, and randomization ensures
that unknownconfounders are distributed equally between
trial groups, so differences in birth outcomes can be as-
sumed to be caused by NRT. Although meta‐analyses were
underpowered and there were no significant differences
between the NRT and control groups, the trend in
non‐statistically significant point estimates derived from
these analyses is noteworthy. For low birth weight, preterm
birth, neonatal intensive care unit admissions, neonatal
death and congenital anomalies, point estimates suggest a
protective effect of NRT, whereas those for miscarriage
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and stillbirth do not. Additionally, caesarean section rates
were non‐significantly higher following NRT but, in the ab-
sence of contextual data, it is not clear if this is an adverse or
a positive outcome. This point estimate trend suggests that,
with more data from RCTs, NRT could well prove to be less
harmful than smoking in pregnancy. Due to design issues,
non‐RCTmeta‐analyses are probably not methodologically
robust enough to inform clinical practice and their findings
do not add to those from RCT meta‐analyses. Pregnant
women in non‐RCTstudies are only likely to have been pre-
scribed or offered NRT by clinicians if they smoked. Conse-
quently, to provide valid findings, these studies should
have assessed pregnant women’s smoking behaviour and
adjusted analyses for this. As the probable mechanism for
NRT improving birth outcomes is due to women stopping
smoking or smoking less, this is particularly important.
Further work
RCTs and robust population‐based cohort studies from rou-
tine health‐care settings are needed to improve the evi-
dence base for the safety of NRT use in pregnancy.
Electronic medical records databases offer the potential
for valid capture of near‐complete pregnancy outcome
data. However, to make a valid contribution to the litera-
ture, future non‐RCTstudies need better methods for quan-
tifying exposures to NRT and smoking during the whole of
pregnancy and to adjust for the latter in analyses.
CONCLUSIONS
The strongest data on the probable impacts of NRT expo-
sure in pregnancy on birth outcomes comes from RCTs,
and these provide no suggestion that NRT might be harm-
ful. Non‐RCTstudies have less consistent findings, duemost
probably to inherent design weaknesses, and future obser-
vational studies should provide analyses which account for
the impact of smoking behaviour within women who also
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